Noxopharm Ltd (ASX: NOX) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Noxopharm Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $19.58 million
P/E Ratio 32.89
Dividend Yield 0.00%
Shares Outstanding 292.24 million
Earnings per share -0.041
Dividend per share N/A
Year To Date Return -8.45%
Earnings Yield 3.04%
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Noxopharm Ltd (ASX: NOX)
    Latest News

    Rising healthcare ASX share price represented by doctor giving thumbs up
    Healthcare Shares

    Here's why the Noxopharm (ASX:NOX) share price is flying 16% today

    The Noxopharm Ltd (ASX: NOX) share price is storming more than 16% higher after the company released a promising update…

    Read more »

    Five stacked building blocks with green arrows, indicating rising inflation or share prices
    Share Gainers

    Here's why the Noxopharm (ASX:NOX) share price is surging 6% higher

    Here's why the Noxopharm Ltd (ASX:NOX) share price is charging higher on Tuesday morning following the release of a positive…

    Read more »

    ⏸️ ASX Shares

    3 ASX Healthcare shares feeling a little under the weather

    These 3 ASX healthcare shares have been out-of-form over the past month. We take a look at what could be…

    Read more »

    Share Market News

    What is going with the Noxopharm (ASX:NOX) share price today?

    The Noxopharm Ltd (ASX: NOX) share price is bouncing around after the drug developer announced the progression of its NOXCOVID-1…

    Read more »

    Medical staff wear hero capes, indicting strong shar [price performace for healthcare shares
    Share Market News

    Noxopharm (ASX:NOX) share price closes 21% higher after clinical milestone

    The Noxopharm (ASX: NOX) share price gained a 21% boost today after the company announced groundbreaking research results.

    Read more »

    Starpharma share price A doctor or medical expert in COVID-19 protection flexes his muscle, indicating growth or strong share price movement in ASX medical, biotech and health companies
    Share Market News

    Why the Noxopharm (ASX:NOX) share price is bouncing up today

    The Noxopharm share price is up more than 7% today on release of the company's December 2020 quarterly results. Let's…

    Read more »

    A medical researcher works on a bichip, indicating share price movement in ASX tech companies
    Share Market News

    Why the Noxopharm (ASX:NOX) share price is jumping 14% higher today

    The Noxopharm Ltd (ASX: NOX) share price is going berserk today. We take a look at what the company released…

    Read more »

    Share Gainers

    Why the Noxopharm (ASX:NOX) share price surged 8% higher today

    The Noxopharm Ltd (ASX:NOX) share price surged higher on Monday after announcing a new study of its Veyonda product...

    Read more »

    laboratory microscope
    Share Market News

    Noxopharm share price soars 12% higher on drug update

    The Noxopharm share price soared 12% higher on a drug update this morning. Let's take a look at what the…

    Read more »

    NOX ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Noxopharm Ltd

    Noxopharm Ltd is an Australian clinical-stage drug development company focused on treating cancer with Veyonda. It is engaged in the development in the field of both oncology and non-oncology in the pan-pacific region.

    NOX Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    28 Mar 2024 $0.07 $0.00 0.00% 37,671 $0.07 $0.07 $0.07
    27 Mar 2024 $0.07 $0.00 0.00% 28,433 $0.07 $0.07 $0.07
    26 Mar 2024 $0.06 $0.00 0.00% 205,083 $0.07 $0.07 $0.06
    25 Mar 2024 $0.07 $-0.01 -14.08% 488,610 $0.07 $0.07 $0.07
    22 Mar 2024 $0.07 $0.00 0.00% 327,691 $0.07 $0.07 $0.07
    21 Mar 2024 $0.07 $0.00 0.00% 218,547 $0.07 $0.07 $0.07
    20 Mar 2024 $0.07 $0.00 0.00% 71,735 $0.07 $0.07 $0.07
    19 Mar 2024 $0.07 $0.00 0.00% 32,054 $0.07 $0.07 $0.07
    18 Mar 2024 $0.07 $0.00 0.00% 21,810 $0.07 $0.07 $0.07
    15 Mar 2024 $0.07 $0.00 0.00% 78,871 $0.07 $0.07 $0.07
    14 Mar 2024 $0.07 $0.00 0.00% 3,546 $0.07 $0.07 $0.07
    13 Mar 2024 $0.07 $0.00 0.00% 242,039 $0.07 $0.07 $0.07
    12 Mar 2024 $0.07 $0.00 0.00% 63,007 $0.07 $0.07 $0.07
    11 Mar 2024 $0.07 $0.00 0.00% 460,224 $0.07 $0.07 $0.07
    08 Mar 2024 $0.07 $0.00 0.00% 342,763 $0.07 $0.07 $0.07
    07 Mar 2024 $0.07 $0.00 0.00% 135,285 $0.07 $0.07 $0.07
    06 Mar 2024 $0.07 $0.00 0.00% 206,637 $0.07 $0.07 $0.07
    05 Mar 2024 $0.07 $0.00 0.00% 207,666 $0.07 $0.07 $0.07
    04 Mar 2024 $0.08 $-0.01 -12.20% 135,718 $0.08 $0.08 $0.07
    01 Mar 2024 $0.08 $0.00 0.00% 163,251 $0.08 $0.09 $0.08
    29 Feb 2024 $0.08 $0.00 0.00% 1,681,124 $0.08 $0.11 $0.08
    28 Feb 2024 $0.08 $0.02 33.33% 414,111 $0.06 $0.08 $0.06

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    15 Sep 2023 Frederick (Fred) Bart Buy 880 $30
    On-market trade.
    14 Sep 2023 Frederick (Fred) Bart Buy 253,001 $9,108
    On-market trade.
    30 Jun 2023 Frederick (Fred) Bart Buy 135,281 $5,681
    On-market trade.
    29 Jun 2023 Frederick (Fred) Bart Transfer 3,080,189 $170,950
    Off-market transfer.
    29 Jun 2023 Frederick (Fred) Bart Transfer 3,080,189 $170,950
    Off-market transfer.
    09 May 2023 Frederick (Fred) Bart Buy 500,000 $21,000
    On-market trade.
    04 May 2023 Frederick (Fred) Bart Buy 1,000,000 $50,000
    On-market trade.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Frederick (Fred) Bart Non-Executive DirectorNon-Executive Chairman May 2020
    Mr Bart was appointed the Managing Director of Textile Industries Australia In 1985,. The Group employed over 1,200 people and distributed product to many countries worldwide. The Company manufactured and distributed the majority of bed linen in Australia under brands like Sheridan and ACTIL. In 1989, Mr Bart established and chairs a number of private companies under the umbrella of the Bart Group which covered hotels, retail, commercial and residential land development and technologies which still continue to operate. The Group today employs in excess of 1,000 people and is active in many local and overseas markets. In 2013, Mr Bart became Director and majority shareholder of Immunovative Therapies Limited, a private Israeli company involved in the manufacture of vaccines for the treatment of certain forms of cancer. The Company has undertaken trials in both collateral and liver cancers. He is a member of Risk Committee.
    Mr Peter Ashley Marks Non-Executive DirectorNon-Executive Deputy Chairman Mar 2016
    Mr Marks has over 35 years of experience in corporate advisory and investment banking. Over the course of his career, he has specialised in capital raising IPO's, cross border capital raisings, M&A transactions, corporate underwriting and venture capital transactions for companies based in Australia, the US and Israel. He has been involved in a range of transactions with a focus in the life-sciences, biotechnology, medical technology and high tech as well as the mining sector. Peter has served as both an Executive and Non-Executive Director of a number of different entities, many of which have been listed on the ASX, Nasdaq and AIM markets. He is Chair of Risk Committee.
    Mr Boris Patkin Non-Executive Director Mar 2020
    Mr Patkin brings market knowledge, thorough research and years of experience in investment markets and business consulting. As a financial and investment advisor, Boris has an understanding of industry trends and has insight into domestic and international markets. He specialises in the reconstruction of companies, investments and in international trade and is also a business consultant in the medical and disruptive technology arena. He is currently a member of MeSAFAA and is a senior advisor with Morgans Financial Ltd. He is also non-executive chairman of Ausmon Resources Ltd - since 2014. He is member of Risk Committee.
    Dr Gisela Mautner Chief Executive OfficerManaging Director Feb 2022
    Dr Mautner has more than 20 years of experience in global pharmaceutical organisations, including operational, medical and scientific advisory roles across multiple therapeutic areas. During her career she held senior positions at global pharmaceutical companies like MSD (Merck), Bayer and Amgen in Germany as well as Australia.
    Mr David James Franks Company Secretary Jan 2017
    -
    David James Franks Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Milligene Pty Ltd (The Ge and Pr Kelly Family A/C)(i) 26,249,106 8.98%
    Mrs Eleanore Goodridge 13,050,000 4.47%
    Milligene Pty Ltd (The Ge and Pr Kelly Family A/C)(ii) 8,000,000 2.74%
    Citicorp Nominees 6,751,024 2.31%
    Rgt Capital Fund No 5 (Noxo) Pty Ltd 6,500,333 2.22%
    Mr Fred Bart 5,618,651 1.92%
    Link Traders (Aust) Pty Ltd(i) 5,545,298 1.90%
    Link Traders (Aust) Pty Ltd (ii) 5,041,224 1.73%
    Kale Capital Corporation Limited 4,997,437 1.71%
    Jamber Investments Pty Ltd (The Amber Schwarz Fam A/C) 4,252,761 1.46%
    Rhlc Pty Limited (Rhlc S/F A/C) 3,200,000 1.09%
    Mr Lizhong Yu 2,918,000 1.00%
    Blackcourt (Nsw) Pty Limited (Lawsam Super Fund A/C) 2,686,376 0.92%
    Mr Robert Thomas Lin 2,500,000 0.86%
    Ogen Nominees Pty Ltd 2,300,000 0.79%
    Halcyon Nominees Pty Ltd (Halcyon Super Fund A/C) 2,000,000 0.68%
    Mrs Sophie Ethel Gelski 1,942,424 0.66%
    Helium Management Pty Ltd (Helium S/F A/C) 1,751,246 0.60%
    Mr Michael Shabat & Ms Meital Hana Shabat (M&M Shabat Super Fund A/C) 1,702,824 0.58%
    Berne No 132 Nominess Pty Ltd (331898 A/C) 1,660,238 0.57%

    Profile

    since

    Note